The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis

Sohag University215 enrolled

Overview

Interventional phase 3 study aiming to unravel the value of pulse steroids in achieving remission or low disease activity in refractory active JIA

First group will receive 2 consecutive days intravenous pulse of 125 mg methylprednisolone. Second group will not receive additional drugs. Assessment was done at baseline and every month for 3 months for both groups using Juvenile Arthritis Disease Activity Score (JADAS) and the American College of Rheumatology Pediatric 30, 50, and 70 response criteria (ACR Pedi. 30, 50, 70).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

215

Conditions

Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active)

Interventions

SolumedrolDRUG

2 days pulse steroid injection 125 mg methylrednisolone

Eligibility

Sex: ALLMin age: 2 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients still active despite administration o 2 DMARDs Exclusion Criteria: * Other connective tissue diseases * Endocrine disorders such as Thyroid disorders.

Locations (1)

Al-Azhar University

Cairo, Egypt

RECRUITING

Outcomes

Primary Outcomes

remission or low disease activity

patients will be assessed at baseline and every month for 3 months using Juvenile Arthritis Disease Activity Score (JADAS) for disease activity American College of Rheumatology Pediatric 30, 50, and 70 (ACR Pedi. 30, 50, 70) for disease activity

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.